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http://dx.doi.org/10.1016/j.ccr.2014.04.008SUMMARYThe TFAP2C/AP-2g transcription factor regulates luminal breast cancer genes, and loss of TFAP2C induces
epithelial-mesenchymal transition. By contrast, the highly homologous family member, TFAP2A, lacks tran-
scriptional activity at luminal gene promoters. A detailed structure-function analysis identified that sumoyla-
tion of TFAP2A blocks its ability to induce the expression of luminal genes. Disruption of the sumoylation
pathway by knockdown of sumoylation enzymes, mutation of the SUMO-target lysine of TFAP2A, or treat-
ment with sumoylation inhibitors induced a basal-to-luminal transition, which was dependent on TFAP2A.
Sumoylation inhibitors cleared the CD44+/hi/CD24/low cell population characterizing basal cancers and
inhibited tumor outgrowth of basal cancer xenografts. These findings establish a critical role for sumoylation
in regulating the transcriptional mechanisms that maintain the basal cancer phenotype.INTRODUCTION
Breast cancer has an incidence of 226,000 and accounts for
approximately 40,000 deaths annually in the United States (Sie-
gel et al., 2012). There has been an improvement in survival for
women with breast cancer, although patients with locally
advanced or metastatic disease continue to have a poor prog-
nosis. The clinical subtypes of breast cancer are defined by
the expression of estrogen receptor-alpha (ERa) and progester-
one receptor (PgR) and the amplification and overexpression of
c-ErbB2/HER2. The four common molecular subtypes of breast
cancers include the Luminal A (ERa/PgR+, HER2), Luminal B
(ERa/PgR+, HER2+), HER2 (ERa/PgR, Her2+), and triple-
negative (ERa/PgR, HER2) (Carey et al., 2006; Sørlie et al.,
2001). The luminal breast cancer subtypes (comprising approx-
imately 75% of breast cancer in postmenopausal women) are
characterized by the expression of a set of ERa-associated
genes (Sørlie et al., 2001). Although it is well established thatSignificance
Clinical breast cancer subtypes are characterized by patterns
therapy. Luminal breast cancers express steroid hormone rec
basal breast cancers are not hormone responsive, display an e
worse prognosis. Herein, we show that sumoylation of the TF
breast cancer phenotype. Disruption of SUMO conjugation of T
cell population and an associated inability for basal cancer
pathway may be an effective treatment strategy for basal brea
748 Cancer Cell 25, 748–761, June 16, 2014 ª2014 Elsevier Inc.patterns of gene expression in breast cancer are predictive of
clinical phenotype, little is known about the transcriptional
mechanisms responsible for establishing the characteristic
expression profile. Since many of the ERa-associated genes
are not part of the ERa pathway, the coexpression of these
genes suggests the existence of transcriptional mechanisms
common to luminal genes.
The triple-negative breast cancer subtype is a heterogeneous
group that represents 10%–20% of breast cancers (Bertucci
et al., 2012; Lehmann et al., 2011). The triple-negative subtypes
have an aggressive clinical course and do not respond to therapy
effective for cancers that express ERa or HER2. Hence, there
has been intense research focus on understanding themolecular
characterization of this group with the goal of defining novel
molecular targets (Bertucci et al., 2012). Detailed molecular
profiling has allowed further subclassification of the triple-nega-
tive breast cancer phenotypes into at least six distinct sub-
types, including basal-like 1, basal-like 2, immunomodulatory,of gene expression that predict outcome and response to
eptors and tend to be hormone responsive. By comparison,
xpansion of a CD44+/hi/CD24/low cell population, and have a
AP2A transcription factor is required to maintain the basal
FAP2A was associated with a loss of the CD44+/hi/CD24/low
lines to form tumor xenografts. Inhibiting the sumoylation
st cancer.
Cancer Cell
Sumoylation Required for Basal Breast Cancermesenchymal-like, mesenchymal stem-like, and luminal
androgen receptor subtypes (Lehmann et al., 2011). Other pro-
posed subclassifications of the triple-negative breast cancer
phenotype have identified a claudin-low subgroup characterized
by the relatively reduced expression of genes involved in cell
adhesion and formation of tight junctions (Herschkowitz et al.,
2007; Valentin et al., 2012). Basal-like breast cancers are further
distinguished from luminal cancers by frequent mutations of
TP53, gene expression patterns characteristic of epithelial-to-
mesenchymal transition (EMT) and an increase in the percentage
of cancer stem cells (CSCs) (Bertucci et al., 2012; Valentin et al.,
2012).
TFAP2C (AP-2g) is a member of the developmentally regu-
lated family of AP-2 factors that include five members—TFAP2A
(AP-2a), TFAP2B (AP-2b), TFAP2C (AP-2g), TFAP2D (AP-2d),
and TFAP2E (AP-2ε) (Bosher et al., 1996; Feng and Williams,
2003; Moser et al., 1995; Williams et al., 1988; Zhao et al.,
2001). TFAP2C binds to a GC-rich consensus sequence in the
promoters of target genes through a helix-loop-helix motif in
the DNA binding domain (Eckert et al., 2005). Analysis of a chro-
matin immunoprecipitation with direct sequencing (ChIP-seq)
data set for TFAP2C defined the consensus site as the nine
base sequence SCCTSRGGS (S = G/C, r = A/G) (Woodfield
et al., 2010), which closely matches the previously defined
optimal in vitro binding site (McPherson and Weigel, 1999).
AP-2 factors are expressed early in differentiation of the ecto-
derm and specify cell fates within the epidermis and neural crest
(Hoffman et al., 2007; Li and Cornell, 2007). Within the adult
mammary gland, TFAP2C is expressed in the luminal and myoe-
pithelial cells (Cyr et al., 2014; Friedrichs et al., 2005, 2007).
Overexpression of TFAP2A or TFAP2C in mouse mammary
epithelial cells (MMECs) results in lactation failure with hypopla-
sia of the alveolar mammary epithelium during pregnancy (Ja¨ger
et al., 2003; Zhang et al., 2003). Conditional knockout of the
mouse homolog of TFAP2C, Tcfap2c, in MMECs promoted
aberrant growth of the mammary tree, leading to a reduction in
the luminal cell population and concomitant gain of the basal
cell population at maturity (Cyr et al., 2014). In tumor models,
both TFAP2A and TFAP2C are important to cell proliferation,
establishment of colonies in soft agar, cell migration, and xeno-
graft outgrowth (Orso et al., 2008).
In breast cancer, AP-2 factors regulate expression of both ERa
and Her2. TFAP2C regulates expression of ERa as well as other
ERa-associated genes characteristic of luminal breast cancer
(Cyr et al., 2014; deConinck et al., 1995; McPherson et al.,
1997; Woodfield et al., 2007). TFAP2A and TFAP2C induce
expression of the cloned HER2/ErbB2 promoter (Begon et al.,
2005; Bosher et al., 1996; Delacroix et al., 2005; Yang et al.,
2006). TFAP2C bound to the HER2 promoter, and knockdown
of TFAP2C reduced HER2 expression (Ailan et al., 2009). In
BT474 breast carcinoma cells, TFAP2A and TFAP2C coordi-
nately regulate HER2 expression (Allouche et al., 2008), and a
correlation has been established between AP-2 expression
and the expression of HER2 in primary breast cancers (Allouche
et al., 2008; Pellikainen et al., 2004; Turner et al., 1998).
Several critical questions remain to be addressed. There is
83% similarity between TFAP2A and TFAP2C, with 76% identity
in the carboxyl half of the proteins containing the DNA binding
and dimerization domains (McPherson et al., 1997). In neuralcrest development, TFAP2A and TFAP2C appear to have com-
plementary and overlapping roles (Hoffman et al., 2007). How-
ever, in breast cancer models, TFAP2C was found to have a
unique role in regulation of ESR1/ERa gene expression, which
was functionally distinct from the effects of TFAP2A (Woodfield
et al., 2007). Furthermore, recent findings have highlighted a crit-
ical role for TFAP2C in maintaining the luminal phenotype
through the induction of luminal-associated genes and repres-
sion of basal-associated genes (Cyr et al., 2014). It remains to
be seen if TFAP2A has a similar effect on the expression of
luminal genes. Furthermore, if the role of TFAP2C were function-
ally distinct, it would be of critical importance to understand the
molecular basis for transcriptional specificity of luminal gene
regulation. We expect that mechanisms regulating patterns of
gene expression in breast cancer would provide important
insight into strategies for drug development. With these consid-
erations in mind, we sought to confirm the functional differences
between TFAP2A and TFAP2C in regulation of luminal gene
expression and to determine the molecular basis for functional
specificity of TFAP2C-mediated gene regulation.
RESULTS
Functional Specificity of TFAP2C for the Luminal Gene
Expression Cluster
Previous studies in luminal breast cancer cell lines demonstrated
that knockdown of TFAP2C downregulated ERa, whereas
knockdown of TFAP2A failed to have a similar effect on ERa
expression (Cyr et al., 2014; Woodfield et al., 2007). In order to
validate the unique functional role of TFAP2C in primary human
cancer, we obtained fresh tumor tissue from patients with
ERa-positive breast cancer. Tumor-derived breast cancer cells
were transduced with lentiviruses encoding TFAP2A, TFAP2C,
or nontargeting small hairpin RNA (shRNA). As seen in Figures
1A–1C and Figure S1A (available online), knockdown of TFAP2C,
but not TFAP2A, repressed expression of ERa, confirming that
TFAP2C has unique functional effects with regard to ESR1/
ERa gene regulation and that the cell line models are reflective
of gene regulation in primary human breast cancer. Using
MCF-7 cells, a more expansive examination of luminal gene
targets was performed. The luminal breast cancer subtype ex-
presses a set of luminal-associated genes including ESR1/
ERa, MUC1, FGFR4, KRT8, RET, MYB, FOXA1, and GATA-3
(Kao et al., 2009). Knockdown of TFAP2C repressed expression
of luminal genes, as noted by analysis of RNA (Figures 1D and
S1B) and protein (Figure 1E), whereas knockdown of TFAP2A
had minimal or no effect. The basal target genes, MMP14,
CALD1, and CD44, which are overexpressed in basal cancers,
were repressed by TFAP2C but not TFAP2A. By contrast, a
known TFAP2A target gene, CDKN1A/p21-CIP (Scibetta et al.,
2010; Woodfield et al., 2007), was responsive to TFAP2A only
(Figures 1D and 1E). Hence, although TFAP2A has the ability to
induce certain genes, it lacks functional activity with regard to
the luminal-associated gene expression cluster.
One possibility for the functional differences of TFAP2A and
TFAP2C might be due to differences in the ability for the factors
to bind to the regulatory regions of the luminal cluster genes. In
addition to the genes examined earlier, the FREM2 gene was
identified as a specific TFAP2C target gene, which was highlyCancer Cell 25, 748–761, June 16, 2014 ª2014 Elsevier Inc. 749
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Figure 1. Functional Specificity of TFAP2C for the Luminal Cluster Genes
(A) Primary ERa-positive breast cancer cells derived from patient samples were transduced with lentiviral vectors encoding shRNA specific for nontargeting (NT)
TFAP2A (indicated by A) or TFAP2C (indicated by C). Knockdown of TFAP2A and TFAP2C was confirmed compared to NT; *p < 0.05, compared to NT.
(B) ERa RNA was assessed by RT-PCR; data for all three tumor isolates demonstrate that knockdown of TFAP2C specifically repressed ERa expression; *p <
0.05, compared to NT.
(C) Western blot for ERa protein confirmed that ERa protein expression was repressed by knockdown of TFAP2C only.
(D) Functional effects on RNA expression of luminal genes, the basal genes,MMP14,CALD1, andCD44, and the TFAP2A-specific target geneCDKN1A/p21-CIP
in MCF-7 cells after knockdown of either TFAP2A or TFAP2C; data demonstrate functional specificity of TFAP2C, with statistical differences shown comparing
knockdown of TFAP2A versus TFAP2C for all genes (p < 0.05); *p < 0.05, compared to NT control.
(E) Western blot confirmed functional specificity for TFAP2C in regulation of luminal and basal genes. Error bars indicate SEM.
See also Figure S1.
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Sumoylation Required for Basal Breast Cancerresponsive to changes in TFAP2C expression but was unrespon-
sive to TFAP2A (Figure S1). Using ChIP-seq the binding of
TFAP2A and TFAP2C was compared in MCF-7 cells (Figure 2A).750 Cancer Cell 25, 748–761, June 16, 2014 ª2014 Elsevier Inc.An analysis of the genomic binding of TFAP2A and TFAP2C to
the regulatory regions of the luminal-associated genes, ESR1/
ERa, FOXA1, and FREM2, demonstrated colocalization of the
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Figure 2. ChIP of TFAP2A and TFAP2C with Functional Specificity of TFAP2C Mapped to Amino Terminus
(A) ChIP-seq demonstrates identical binding pattern comparing TFAP2A and TFAP2C to luminal target genes ESR1/ERa, FOXA1, and FREM2; red dot indicates
peak analyzed in detail in (C).
(B) Western blot of MCF-7 cells transfected with empty vector (EV) or HA epitope-tagged AP-2 constructs, TFAP2C (HA-C) or TFAP2A (HA-A), and probed with
antibody shown.
(C) Real-time ChIP was performed with anti-HA antibody, and precipitated chromatin was amplified at off-target and on-target locations for ESR1/ERa, FOXA1,
and FREM2 (Woodfield et al., 2010). Data confirm specific binding of TFAP2A and TFAP2C to peaks identified by ChIP-seq with minimal binding to off-peak sites.
(D) Schematic of TFAP2A (blue) and TFAP2C (yellow) showing homologous regions and chimeric AP-2 proteins generated (all chimeras generated using TFAP2C-
mut, which is construct insensitive to the siRNA). AD, activation domain; Di, dimerization domain; DBD, DNA binding domain. Assignment of functional domains
was as described elsewhere (Williams and Tjian, 1991a, 1991b).
(E) Using endogenous ERa RNA expression as functional assay, MCF-7 cells were transfected with siRNA and expression vector as diagrammed as in (D). The
data show that rescue of ERa transcriptional activity maps to the amino half of the TFAP2C protein.
(F) This experiment is identical to the one described in (E), except that this one uses expression of endogenous FREM2 and maps functional effect to the first 128
amino acids of TFAP2C. *p < 0.05, compared to normalized expression in untransfected control. Error bars indicate SEM.
See also Figure S2.
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Sumoylation Required for Basal Breast Cancertwo factors. ChIP-seq data for the other luminal target genes
examined demonstrated identical binding patterns for TFAP2A
and TFAP2C in the promoter regulatory regions, and these
data agreed with other published ChIP-seq data for MCF-7 cells
(Figure S2). Epitope-tagged AP-2 constructs were used to
confirm the identical chromatin binding patterns (Figures 2B
and 2C). Hemagglutinin (HA)-tagged constructs for TFAP2A
and TFAP2C were transfected into MCF-7 cells, and ChIP was
performed with anti-HA antibody with amplification at on-target
and off-target sites for ESR1/ERa, FOXA1, and FREM2 (Wood-field et al., 2010). The data demonstrate that TFAP2A and
TFAP2C bind to the AP-2 sites in the luminal target genes with
approximately equal binding affinity. Hence, the functional differ-
ences between TFAP2A and TFAP2C cannot be attributed to dif-
ferences in genomic binding.
Functional Specificity of TFAP2C Localized to Amino
Terminus
We sought to identify the domain of TFAP2C responsible for
regulation of the luminal cluster genes. A knockdown/knockinCancer Cell 25, 748–761, June 16, 2014 ª2014 Elsevier Inc. 751
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Figure 3. Yeast Two-Hybrid Identifies Sumoylation Pathway Regulating Activity of TFAP2A on FREM2
(A) Yeast two-hybrid screen using TFAP2A or TFAP2C as bait identified potential AP-2 interacting factors. Proteins from named genes are shown that were
uniquely pulled out using either TFAP2A (blue) or TFAP2C (yellow) or were pulled out with both factors (green) as bait.
(B) A set of 21 factors was chosen for screening by knockdown with specific siRNAs inMCF-7 cells and assaying for effects on expression of endogenous FREM2
compared to nontargeting (NT) siRNA (normalized to 1.0); *p < 0.05, compared to NT. Two proteins identified as TFAP2A-interacting factors in yeast two-hybrid
screen (PIAS1 and Ubc9/UBE2I) significantly induced FREM2 expression with knockdown. Error bars indicate SEM.
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Sumoylation Required for Basal Breast Cancersystem was developed in which the expression of endogenous
TFAP2C was knocked down by small interfereing RNA (siRNA)
and rescued by cotransfection with expression vectors for either
TFAP2A or TFAP2C, engineered to be resistant to the siRNA.
Chimeric AP-2 proteins were created where regions of TFAP2A
were substituted with the homologous region of TFAP2C (Fig-
ure 2D). With endogenous ERa expression used as a marker
for activation, rescue of ERa expression was localized to the
amino half of TFAP2C (Figure 2E). FREM2 was more robust as
amarker for TFAP2C-specific activation and allowed localization
of luminal-specific activation to the first 128 amino acids of the
activation domain (Figure 2F).
Sumoylation Pathway Inhibits Transcriptional Activity
of TFAP2A
The luminal cluster gene promoters appear to share a common
transcriptional mechanism, and we sought to understand the
molecular basis for the functional block of TFAP2A. The block
of TFAP2A activity at luminal promotersmight involve either a co-
activator (or coactivators) specific for TFAP2C or promoter-spe-
cific corepressors of TFAP2A. A set of potential AP-2 cofactors
were identified using yeast two-hybrid in which either TFAP2C
or TFAP2Awas used as bait (Figure 3A). A set of factors was cho-
sen based on previous findings suggesting a potential role in
gene regulation. The functional effect of each cofactor was as-
sessed by serial knockdown using specific siRNAs and assaying
for expression of endogenous FREM2 (Figure 3B). Of 21 AP-2
binding partners tested, knockdown of two TFAP2A-interactive
factors, PIAS1 and Ubc9/UBE2I, significantly induced endoge-
nous FREM2 expression in MCF-7 cells. Ubc9 is a unique E2752 Cancer Cell 25, 748–761, June 16, 2014 ª2014 Elsevier Inc.small ubiquitin-like modifier (SUMO)-conjugating enzyme (Ihara
et al., 2008; Johnson and Blobel, 1997), and PIAS1 is a SUMO
E3 ligase (Leitao et al., 2011). Ubc9 was previously shown to
bind to TFAP2A and TFAP2C (Eloranta and Hurst, 2002). As
both proteins are part of the sumoylation pathway, the findings
implicated sumoylation as a potential mechanism accounting
for a functional block of TFAP2A in regulation of the luminal
gene cluster. Glutathione S-transferase (GST) pull-down and
coimmunoprecipitation confirmed that Ubc9 bound to both
TFAP2A and TFAP2C (Figures 4A–4C). Knockdown of Ubc9
increased endogenous FREM2 expression (Figure 4D). Whereas
knockdown of TFAP2A alone had no effect, knockdown of
TFAP2A abrogated the effect of Ubc9 knockdown, indicating
that, in the absence of the sumoylation pathway, FREM2 expres-
sion became responsive to TFAP2A. It is interesting that western
blot analysis of TFAP2A often demonstrates a doublet (Figures
4D and S1G; Woodfield et al., 2010). Knockdown of Ubc9
reduced the relative amount of the upper band (Figure 4D), sug-
gesting the potential for sumoylation of TFAP2A. One major site
for sumoylation is lysine 10, and the TFAP2A isoform 1A, which
was used to generate the chimeric AP-2 proteins, contains the
K10 SUMO site (Berlato et al., 2011). To formally demonstrate
sumoylation of TFAP2A, SUMO-1, -2, and -3 were expressed
in vitro with TFAP2A. Wild-type TFAP2A was sumoylated by all
three SUMO proteins, but the TFAP2A mutant K10R had signif-
icantly reduced sumoylation (Figure 4E). In MCF-7 cells, wild-
type TFAP2A, but not K10R mutant, was sumoylated in vivo
with all three SUMO proteins (Figure 4F). Immunoprecipitated
TFAP2A was evaluated by western blot with anti-SUMO2/3 anti-
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Figure 4. Sumoylation Functionally Linked to AP-2 Activity
(A) Ubc9 binds to TFAP2A and TFAP2C in GST pull-down. TnT, in vitro transcription-translation.
(B) MCF-7 cells were transfected with expression vectors for green fluorescent protein (GFP)-AP-2 fusion proteins demonstrating nuclear expression of GFP
fusion proteins with colocalization with DAPI nuclear stain.
(C) Coimmunoprecipitation of GFP-TFAP2A and GFP-TFAP2C confirms protein-protein interaction between Ubc9 and both AP-2 proteins. IP, immunoprecip-
itation; IgG, immunoglobulin G. WB, western blot was probed with antibody to the protein shown.
(D) Expression of endogenous FREM2 RNA in MCF-7 cells transfected with siRNA (normalized to nontargeting [NT]), indicated with western blots below. Data
show that FREM2 expression is not responsive to TFAP2A; however, knockdown of Ubc9 induced FREM2 expression, and induction is blocked with knockdown
of TFAP2A, showing that FREM2 expression responds to TFAP2A in the absence of sumoylation pathway; *p < 0.05, compared to NT. Error bars indicate SEM.
(E) Sumoylation using in vitro assay demonstrates wild-type TFAP2A is sumoylated by SUMO-1, -2, or -3, whereas TFAP2A K10R mutant has significantly
reduced sumoylation. The asterisk with arrow indicates the SUMO-conjugated form of the protein.
(F) MCF-7 cells cotransfected with expression vector for TFAP2A or K10R mutant construct for SUMO-1, -2, or -3. Data show that wild-type TFAP2A is
sumoylated in vivo, whereas the K10R mutant is not. The asterisk with arrow indicates the SUMO-conjugated form of the protein.
(G) Protein fromMCF-7 cells was immunoprecipitated (IP) using IgG or anti-TFAP2A antibody; protein was eluted frombeads (E), and prewashes (P1 and P2) were
assayed; load is unprecipitated extract; western blot was probed with anti-SUMO2/3 antibody.
(H) TFAP2C was sumoylated in vitro with SUMO-1, -2, or -3; an asterisk indicates sumoylated form of TFAP2C.
(I) MCF-7 cells transfected with expression vectors for SUMO-1, -2, or -3, and western blot probed with TFAP2C shows evidence for sumoylation with SUMO-1;
an asterisk indicates location of sumoylated TFAP2C.
See also Figure S3.
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Sumoylation Required for Basal Breast CancerTFAP2A in MCF-7 cells (Figure 4G). Although sumoylated forms
of TFAP2C were identified in vitro with SUMO-1, -2, or -3 (Fig-
ure 4H), expression in MCF-7 cells in vivo was only able to
identify sumoylation of TFAP2C with coexpression of SUMO-1
(Figure 4I). The sumoylated forms of AP-2 were estimated to
be 70 ± 5 kDa (Figures S3A–S3D). Sumoylation of TFAP2A was
similarly demonstrated in the basal line BT549, which was
increased with peroxide (Figures S3E and S3F).
Inhibiting SUMOConjugation of TFAP2A Induced aBasal
to Luminal Transition
To demonstrate the functional effects of sumoylation, wild-type
and the K10R mutant of TFAP2A were transfected into MCF-7cells. Transfection of TFAP2A-K10R induced expression of
luminal-associated genes (RET, MUC1, and FREM2), whereas
transfection of wild-type TFAP2A had no effect (Figure 5A). By
contrast, transfection of wild-type TFAP2A or K10R mutant
induced expression of CDKN1A/p21-CIP. The induction of
FREM2 protein with expression of TFAP2A-K10R was confirmed
by western blot, without changes in expression of TFAP2C (Fig-
ure 5B). Although the effects on luminal gene expression were
reproducible, the overall effects were modest, since parental
MCF-7 cells express TFAP2C aswell as the luminal gene targets.
We have shown that stable knockdown of TFAP2C converts
MCF-7 cells from a luminal to basal-like phenotype (Cyr et al.,
2014). Hence, a MCF-7 cell clone with stable knockdown ofCancer Cell 25, 748–761, June 16, 2014 ª2014 Elsevier Inc. 753
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Figure 5. Functional Effects of TFAP2A-K10R Mutant and Sumoylation Inhibition
(A) Expression of luminal genes inMCF-7 cells transfected with wild-type TFAP2A or K10Rmutant. K10Rmutant induced luminal genes but wild-type TFAP2A did
not. Both wild-type and K10R mutant TFAP2A induced CDKN1A/p21.
(B) Protein expression fromwestern blots performed in triplicate, with an example of western blot below showing FREM2 protein expression induced by K10R but
not wild-type TFAP2A.
(C) Expression of luminal cluster genes ESR1/ERa,KRT8, and FREM2 in sKD-C cells transfectedwith empty vector (EV) or expression vector for TFAP2Aor K10R-
TFAP2A mutant, with expression normalized to EV. K10R induced expression of luminal target genes, whereas wild-type TFAP2A did not.
(D) Knockdown of Ubc9 or PIAS1 reactivated ERa and repressed CD44 expression in sKD-C cells.
(E) Treatment of sKD-C cells with GA reactivated FREM2 and ERa and repressed CD44 mRNA normalized to lowest value (top) and protein (bottom). For all
panels, an asterisk indicates p < 0.05 compared to normalized signal of 1.0. For CD44 expression in (E), GA treated and untreated were also significantly different
from each other, p < 0.05. Error bars indicate SEM.
Cancer Cell
Sumoylation Required for Basal Breast CancerTFAP2C (sKD-C) was utilized compared to a cell clone with a
nontargeting shRNA (sKD-NT). Overexpression of TFAP2A-
K10R in sKD-C basal-like cells significantly induced the luminal
genes ESR1/ERa, KRT8, and FREM2, whereas wild-type
TFAP2A had no effect (Figure 5C). Inhibiting sumoylation by
knockdown of either PIAS1 or Ubc9 in sKD-C cells resulted in re-754 Cancer Cell 25, 748–761, June 16, 2014 ª2014 Elsevier Inc.activation of ERa mRNA and protein expression and repressed
expression of the basal-associated gene CD44 (Figure 5D). To
confirm the effect of the sumoylation pathway, the small mole-
cule inhibitor of sumoylation, ginkgolic acid (GA) (Fukuda et al.,
2009), was examined for its effect on ERa, FREM2, and CD44
expression. Treatment of sKD-C cells with GA induced ERa
Cancer Cell
Sumoylation Required for Basal Breast Cancerand FREM2 expression and repressed CD44 expression com-
pared to vehicle treatment without altering TFAP2C expression
(Figure 5E).
Sumoylation Inhibitors Clear theCD44+/hi/CD24–/low Cell
Population
The findings suggest that the sumoylation pathway plays a crit-
ical role in maintaining the basal breast cancer phenotype. One
of the characteristics of basal breast cancers is the relatively
high percentage of the CD44+/hi/CD24/low cell population. To
confirm the generality of the findings, basal breast cancer cell
lines were treated with GA or another inhibitor of sumoylation,
anacardic acid (AA) (Fukuda et al., 2009). As previously reported,
we confirmed that AA inhibited SUMO conjugation of proteins
globally and the SUMO-conjugated form of TFAP2A specifically
(Figure S4). AA was also noted to decrease slightly the overall
expression of TFAP2A. As seen in Figure 1, knockdown of
TFAP2C induced a 1.5-fold increase in TFAP2A, indicating that
TFAP2C moderately represses TFAP2A. The finding that AA
induced a slight decrease in TFAP2A is consistent with the
SUMO-unconjugated form of TFAP2A acquiring TFAP2C-like
repression activity. Treatment of the basal breast cancer cell
lines BT-20 and BT-549, as well as sKD-C cells with sumoylation
inhibitors, abrogated expression of CD44 and significantly
reduced the CD44+/hi/CD24/low population (Figure 6A). In addi-
tion, cells from a primary basal breast cancer were treated
in vitro in parallel. The cancer was from a patient with locally
advanced breast cancer that was refractory to conventional
chemotherapy. Remarkably, treatment with GA or AA cleared
the CD44+/hi/CD24/low population from the cells harvested
from the primary tumor (Figure 6A, last panel). By contrast, GA/
AA treatment of MCF-10A cells, a normal breast cell line model,
had no effect on CD44 expression.
To further demonstrate the role of AP-2 in repression of CD44,
the effects of GA and AA were examined with knockdown of
TFAP2A. As seen in Figures 6B and 6C, knockdown of TFAP2A
alone had no effect on CD44 expression in sKD-C, BT549, and
BT20 cells. However, the ability for GA and AA to repress
CD44 expression in the basal breast cancer cell lines was
completely eliminated by knockdown of TFAP2A. Since drug ef-
fectsmight not be specific for a single pathway, GA andAAmight
induce changes in CD44 expression through several mecha-
nisms. To prove that the effects on CD44 expression were medi-
ated through the sumoylation pathway, Ubc9 and PIAS1 were
knocked down by siRNA in the basal cell lines BT549 and
BT20, and the effects on CD44 expression were assessed. As
seen in Figures 7A and 7B, knockdown of either Ubc9 or
PIAS1 similarly repressed CD44 expression. Furthermore,
knockdown of Ubc9 or PIAS1 eliminated the SUMO-conjugated
formof TFAP2A (and slightly reduced the overall level of TFAP2A)
in both basal (BT549) and luminal (MCF-7) cells (Figures 7C
and 7D).
The CD44+/hi/CD24/low cell population is associated with a
subset of breast carcinoma cells that are critical for the initiation
of tumor xenografts. To address the effects of GA and AA on
tumor initiation, BT20 cells were pretreated with GA or AA
compared to vehicle prior to inoculation of xenografts in nude
mice. As noted in Figure 7E, pretreatment of the cells repressed
the formation of tumor xenografts, whereas vehicle-treated cellsformed xenografts with a median time of 8 weeks. To prove that
the drugs were not cytotoxic, BT20 xenografts were inoculated
in nude mice, and the mice were gavaged with AA or vehicle.
As noted in Figure 7E, mice gavaged with AA failed to form
tumors, whereas vehicle-gavaged mice formed xenografts as
expected. We created a breast carcinoma cell line (IOWA-1T)
from the basal tumor-derived cells used in Figure 6A. The
IOWA-1T cell line rapidly forms locally advanced tumors in
nude mice (R.J.W. and M.V.B., unpublished data). Identical ex-
periments using the IOWA-1T basal cell line confirmed that either
pretreating the cancer cells or gavaging mice with AA repressed
tumor initiation of xenografts (Figure 7F).
DISCUSSION
Transcriptional Regulation of Luminal Gene Expression
in Breast Cancer
In the presence of an intact sumoylation pathway, TFAP2C tran-
scriptionally regulates the expression of luminal genes such as
ERa/ESR1, whereas TFAP2A is functionally inactive at luminal
gene promoters. A model depicting the role of AP-2 factors in
establishing gene expression patterning in breast cancer is pre-
sented in Figure 8. Furthermore, the data herein support the
conclusion that this model is reflective of gene regulation in pri-
mary ERa-positive cancer. Recent evidence indicates that
TFAP2C likely functions in concert with other transcription fac-
tors, including ERa and FOXA1, to regulate many of the genes
in the luminal expression cluster (Cyr et al., 2014; Jozwik and
Carroll, 2012; Tan et al., 2011). Other studies have attempted
to define mechanisms common to the regulation of luminal
breast cancer genes (Joshi et al., 2012). GATA-3 regulates the
differentiated luminal breast cancer phenotype (Fang et al.,
2009), and recent findings indicate an important role of
FOXM1 in mediating mammary luminal cell differentiation
through GATA-3 (Carr et al., 2012). Previous studies have also
implicated FOXA1 (Bernardo et al., 2013), Elf5 (Chakrabarti
et al., 2012), BRCA1 (Bai et al., 2013), and ErbB3 (Balko
et al., 2012) in maintaining the luminal mammary phenotype. It
is interesting that prostate-derived ETS factor (PDEF) mediates
luminal differentiation and also correlates with expression in
luminal breast cancer, suggesting a strong link between devel-
opment of luminal mammary cells and oncogenesis of luminal
breast cancer (Buchwalter et al., 2013). Similarly, TFAP2C par-
ticipates in luminal mammary development and luminal gene
expression in breast cancer (Cyr et al., 2014), further strength-
ening the link between the processes of luminal differentiation
and oncogenesis.
Sumoylation Blocked the Activity of TFAP2A at Luminal
Gene Promoters
Several lines of evidence indicate that sumoylation plays a key
role in establishing the functional differences between TFAP2C
and TFAP2A and accounts for the functional block of TFAP2A
at luminal gene promoters (see Figure 8). First, we have demon-
strated sumoylation of TFAP2A at lysine 10 in vitro and in vivo.
Second, blocking the sumoylation pathway, either by knock-
down of critical enzymes in the sumoylation pathway or with
the use of small molecule inhibitors of sumoylation, allowed
TFAP2A to induce expression of luminal genes such asCancer Cell 25, 748–761, June 16, 2014 ª2014 Elsevier Inc. 755
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Figure 6. Sumoylation Inhibitors Cleared CD44+/hi/CD24–/low Cell Population
(A) Treatment of s-KD-C, BT-549, BT-20, or cells derived from a primary basal cancer (Basal Cancer) with GA or AA inhibited CD44 expression bywestern blot (top
row) and significantly reduced the CD44+/hi/CD24-/low population by FACS analysis (lower panels) but had no effect on the normal breast cell line MCF-10A. VC,
vehicle control.
(B and C) Western blots showing that CD44 repression by GA and AA treatment was dependent on expression of TFAP2A since knockdown of TFAP2A with
siRNA abrogated effect of sumoylation inhibitors in sKD-C cells (B) and basal cell lines BT549 and BT20 (C).
See also Figure S4.
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Sumoylation Required for Basal Breast CancerESR1/ERa and FREM2 and repress expression of the basal gene
CD44. Finally, mutation of the SUMO target lysine of TFAP2A
conferred the ability to induce expression of luminal cluster
genes. Taken together, the data indicate that sumoylation of
endogenous TFAP2A blocks this factor from regulating luminal
gene expression. Furthermore, it is clear that the functional effect
of sumoylation is a luminal gene-specific effect since wild-type
or K10R mutant TFAP2A was active in transcriptional activation756 Cancer Cell 25, 748–761, June 16, 2014 ª2014 Elsevier Inc.of CDKN1A/p21-CIP. Although there is evidence that TFAP2C
can be sumoylated, we were not able to demonstrate that su-
moylation has functional effects on the transcriptional activity
of TFAP2C. Under conditions where sumoylation of TFAP2A
blocked its activity at luminal gene promoters, TFAP2C remained
active despite evidence for similar levels of sumoylation. Further
studies concerning details of sumoylation of TFAP2C may
uncover subtle effects at specific promoters.
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Figure 7. Knockdown of Sumoylation Enzymes Repressed CD44
and Blocked SUMO Conjugation of TFAP2A
(A and B) Knockdown of Ubc9 and PIAS1 by siRNA repressed expression of
CD44 in BT549 (A) and BT20 (B) cells showing same effect as GA and AA. Error
bars indicate SEM.
(C and D) Endogenous TFAP2Awas examined bywestern blot in BT549 (basal)
(C) and MCF-7 (luminal) (D) cells. The SUMO-conjugated form of TFAP2A is
seen in both cell types (denoted by an asterisk), and knockdown of either Ubc9
or PIAS1 significantly reduced SUMO-conjugated TFAP2A. MW, molecular
weight markers.
Cancer Cell
Sumoylation Required for Basal Breast CancerThe Role of Sumoylation in Cancer-Related Gene
Regulation
Sumoylation involves the posttranslational modification of pro-
teins through the covalent attachment of SUMO proteins to
lysine residues in target proteins (Bettermann et al., 2012; Cube-
n˜as-Potts and Matunis, 2013). At least four SUMO proteins have
been described, SUMO-1 through SUMO-4. The enzymatic
pathway involves several steps beginning with ATP-dependent
activation of the SUMO protein by the E1 heterodimer ASO1-
UBA2, continuing with the transfer of SUMO to the cysteine res-
idue of the E2 enzyme Ubc9, and finally the enzymatic transfer of
the SUMO tag to the target protein by the E3 ligase, e.g., PIAS1.
Sumoylation of key regulatory proteins influences several
aspects of oncogenesis and cancer progression (Bettermann
et al., 2012). There is a growing body of literature reporting the
sumoylation of transcription factors and the effects on transcrip-
tional regulation (Gill, 2003), including sumoylation of androgen
receptor, glucocorticoid receptor, C/EBP, Smad4, Myb, Ets-1,
Pdx1, Sp3, p300, CREB, and p53 (Bettermann et al., 2012). In
most cases, sumoylation represses transcriptional activity.
Mechanisms resulting in transcriptional repression by sumoyla-
tion may include effects of protein stability, altered cellular local-
ization or DNA binding, modulation of corepressor binding, and
altered association with chromatin-modifying enzymes such as
histone deacetylases (Gill, 2003; Girdwood et al., 2003). Holm-
strom et al. (Holmstrom et al., 2008) showed that transcriptional
inhibition by sumoylation occurred at compound, but not single,
sites and was related to the ability for sumoylation to destabilize
the transcription factor-chromatin interaction. A mechanism
whereby sumoylation destabilizes TFAP2A binding to certain
regulatory regions may provide a mechanism for our finding of
promoter-specific repression. Since the function of TFAP2A at
promoters for genes such as CDKN1A/p21-CIP is SUMO insen-
sitive, it is possible that promoter regulatory structure common
to luminal genes may account for SUMO-specific effects.
Many luminal genes contain closely linked promoter elements
for AP-2, ERa, and FOXA1 (Tan et al., 2011), and the interaction
of these factors may be sensitive to sumoylation (Figure 8).
Consistent with previous studies, sumoylation of TFAP2A was
increased by peroxide and confirms that oxidative stress can
increase the sumoylation of factors (Bossis and Melchior,
2006; Ryu et al., 2010). Recent studies have suggested that
the sentrin-specific protease 1 (SENP1) may be involved in
SUMO deconjugation of factors in breast cancer (Abdel-Hafiz
and Horwitz, 2012; Chen et al., 2013). It is intriguing to consider(E) At left, tumor-free survival of nude mice (n = 5 per group) inoculated with
BT20 cells pretreated for 48 hr with either GA or AA compared to no pre-
treatment; pretreated cells failed to form tumors. At right, tumor-free survival of
nudemice (n = 5 per group) inoculated with BT20 cells, withmice gavagedwith
AA versus vehicle.
(F) At left, IOWA-1T cells were pretreated with AA or vehicle, and mice were
followed until requiring euthanasia due to tumor size (Overall Survival). Pre-
treatment with AA inhibited tumor formation; n = 5 mice per group, p = 0.002.
At right, nude mice were inoculated with 13 106, 53 105, or 2.53 105 IOWA-
1T cells, and mice were gavaged with either vehicle or AA; vehicle-gavaged
mice developed tumors in 5, 10, and 12 days, respectively. Mice gavaged with
AA failed to form tumors over the course of the experiment; n = 3 mice per
group, p = 0.025.
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Figure 8. Schematic Model of Gene Regu-
lation in Breast Cancer Subtypes
In scenario 1 with an intact SUMO pathway and
active TFAP2C, breast cancer cells are main-
tained in the luminal phenotype. Transcriptional
regulation of many luminal gene promoters are
coordinately regulated by TFAP2C, ERa, and
FOXA1, as well as potentially other cofactors. As
diagrammed in scenario 2, loss of TFAP2C in the
presence of the SUMO pathway induces EMT,
characterized by repression of luminal genes and
induction of basal-associated genes. As shown in
scenario 3, inhibition of the SUMO pathway in the
absence of TFAP2C activity, SUMO-unconju-
gated TFAP2A induces mesenchymal-to-epithe-
lial transition (MET), characterized by repression
of basal-associated gene expression and induc-
tion of luminal-associated genes.
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Sumoylation Required for Basal Breast Cancerthat SENP1 may regulate transcriptional activity of AP-2 factors
in breast cancer by inducing SUMO deconjugation. Further work
is needed to elucidate details of the transcriptional mechanisms
whereby sumoylation specifically inhibits the functional activity
of certain factors such as TFAP2A.
Sumoylation Inhibitors Clear theCD44+/hi/CD24–/low Cell
Compartment
Basal breast cancers are characterized by a relatively high
percentage of cells expressing the characteristic markers
CD44+/hi/CD24/low, which include tumor-initiating cells associ-
ated with the outgrowth of tumor xenografts (Al-Hajj et al.,
2003; Iqbal et al., 2013). The CD44+/hi/CD24/low population is
relatively chemoresistant and becomes enriched after chemo-
therapy (Lee et al., 2011). Stable knockdown of TFAP2C in
luminal cancer cells induced EMT, characterized by the repres-
sion of luminal gene expression, activation of basal-associated
genes, and an increased population of cells expressing the
CD44+/hi/CD24/low markers (Figure 8) (Cyr et al., 2014). In the
present study, SUMO inhibition allowed TFAP2A to acquire
TFAP2C-like repression activity, inhibiting CD44 expression,
clearing cells expressing CD44+/hi/CD24/low markers, and
blocking the outgrowth of cancer xenografts. Of particular clin-
ical relevance, sumoylation inhibitors were able to efficiently
clear theCD44+/hi/CD24/low population in a primary basal breast
cancer obtained from a patient with a locally advanced breast
cancer that was refractory to conventional chemotherapy. The
high percentage of cells expressing the CD44+/hi/CD24/low
markers was likely due to selection from the treatment with
chemotherapy. The remarkable effect of SUMO inhibitors to clear758 Cancer Cell 25, 748–761, June 16, 2014 ª2014 Elsevier Inc.the CD44+/hi/CD24/low tumor-initiating
cell population suggests that this class
of agents may have an effect on basal
breast cancers either alone or in combi-
nation with conventional chemotherapy.
Since the CD44+/hi/CD24/low population
defines the tumor-initiating cells in many
types of carcinomas, it is possible that
SUMO inhibitorsmay have clinical effects
in a wide range of carcinomas. It is inter-esting that sumoylation inhibitors did not affect MCF10A cells,
which are commonly used as a model for normal breast cells.
Hence, the sumoylation pathway appears to be critical for main-
taining the basal breast cancer subtype and is not a general
mechanism regulating CD44 expression in normal breast cells.
EXPERIMENTAL PROCEDURES
Cell Lines
The human breast cancer cell lines were derived and maintained as described
elsewhere (Cyr et al., 2014). Under a protocol approved by the University of
Iowa Institutional Review Board and with informed consent, primary cancer
cells were obtained from surgical resection specimens, and cell suspensions
were prepared with gentle collagenase/hyaluronidase (Stemcell Technologies)
(Ponti et al., 2005). The IOWA-1T cell line was established from a primary basal
tumor (R.J.W. and M.V.B., unpublished data).
ChIP-Seq
ChIP-Seq was performed as described elsewhere (Woodfield et al., 2010).
Sumoylation Assays
Sumoylation in vitro was conducted using the SUMOlink SUMO-1 Kit
and SUMOlink SUMO-2/3 Kit (Active Motif). SUMO plasmids and
pcDNA3.1-TFAP2A or K10R mutant cells were used for in vitro protein
production. MCF-7 cells were transfected for 48 hr with 2 mg SUMO-
expressing plasmids (Feng et al., 2013), which were kindly provided by
Dr. Xiaolu Yang (University of Pennsylvania). As indicated in some experi-
ments, the proteasome inhibitor MG132 was added as described elsewhere
(Chu and Yang, 2011).
Western Blots
Western blots were performed as described elsewhere (Cyr et al., 2014; Kulak
et al., 2013).
Cancer Cell
Sumoylation Required for Basal Breast CancerAP-2 Constructs
AP-2 constructs were amplified using previously cloned cDNAs for template
(McPherson and Weigel, 1999). Gateway TFAP2A and TFAP2C clones were
inserted in-frame into pG-LAP1 (Torres et al., 2009) via LR clonase reaction
using Gateway LR Clonase II Enzyme Mix (Invitrogen).
GA and AA Treatment
Cells were plated (2.53 105/10 cm2) and treated with 10 mMGA or AA (Sigma)
for 2–4 days and collected for quantitative PCR, western blot and fluores-
cence-activated cell sorting (FACS) analysis.
Flow Cytometry
FACS analysis was performed as described elsewhere (Cyr et al., 2014;
Roederer and Hardy, 2001) (http://www.flowjo.com/v8/html/distancing.html).
Yeast Two-Hybrid Assay
Yeast two-hybrid for AP-2 factors was performed as described elsewhere
(McPherson et al., 2002).
Tumor Xenografts
Following a vertebrate animal protocol approved by the University of Iowa
Institutional Animal Care and Use Committee, xenografts were generated by
inoculating 5 3 106 BT20 cells or indicated number of IOWA-1T cells into
nude mice as described elsewhere (Woodfield et al., 2007). All experiments
conformed to the regulatory standards reviewed in the animal protocol.
Statistical Analysis
Statistical analysis was performed using the two-sided Student’s t test for
continuous variables. Comparisons for xenografts were performed using the
log rank test.
ACCESSION NUMBERS
The ChIP-seq data are accessible in the Gene Expression Omnibus database
under accession number GSE44257.
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